As part of the Fast Track designation, Sanofi is set to launch a Phase I/II trial to evaluate the immunogenicity and safety ...

This decision underscores the need for a preventative measure against the chlamydia, which affects millions worldwide.

Amid a period of great upheaval at the agency, the FDA has missed its deadline to decide on approval for Novavax’s COVID-19 ...

Novavax started the week hoping the FDA would issue a full approval of its Covid vaccine. But the decision never came.

A team of researchers led by Dr. Kim V. Narry, director of the Center for RNA Research at the Institute for Basic Science ...

German biotech Ethris, a company developing RNA therapeutics and vaccines, and Swiss contract development and manufacturing ...

Paris: Sanofi has received the US Food and Drug Administration (USFDA) fast-track designation for its mRNA vaccine candidate ...

Sanofi’s chlamydia vaccine candidate was designed to protect against primary genital tract infection and reinfection by the bacterium Chlamydia trachomatis. The Food and Drug Administration (FDA ...

Ethris, a clinical-stage biotechnology company creating RNA therapeutics and vaccines, and Lonza entered a collaboration to ...

US FDA grants fast track designation to Sanofi’s mRNA vaccine candidate for prevention of chlamydia infection: Paris Friday, March 28, 2025, 12:00 Hrs [IST] The US Food and Drug ...

Spray-drying represents a well-established technique that addresses solubility and other manufacturing and stability challenges.